How long does each GLP-1 medication stay in your system?
GLP-1 (glucagon-like peptide-1) is a hormone secreted by L-cells in your small intestine in response to eating. It signals the pancreas, slows gastric emptying, and communicates satiety to the brain. In its natural form, GLP-1 has an extraordinarily short half-life: approximately 1–2 minutes. The enzyme DPP-4 (dipeptidyl peptidase-4) rapidly breaks it down in the bloodstream.
GLP-1 receptor agonist medications — compounded semaglutide, tirzepatide, and earlier agents in this class — are synthetic molecules designed to activate GLP-1 receptors (and, in tirzepatide’s case, GIP receptors as well) while resisting DPP-4 degradation. The result is a much longer duration of action, making once-weekly dosing pharmacologically feasible.
| Molecule | Half-Life | Time to Clear After Stopping | Dosing Frequency |
|---|---|---|---|
| Native GLP-1 (endogenous) | ~1–2 minutes | Minutes | N/A (released post-meal) |
| Compounded semaglutide | ~7 days | ~5 weeks | Once weekly |
| Compounded tirzepatide | ~5 days | ~4–5 weeks | Once weekly |
Sources: Overgaard et al. (2016) for semaglutide; Urva et al. (2021) for tirzepatide; Deacon CF (2005) for native GLP-1.
What is the half-life of semaglutide?
Compounded semaglutide has a half-life of approximately 7 days. This extended half-life is achieved through two structural modifications: fatty-acid side chain attachment, which promotes albumin binding in the bloodstream and slows renal clearance, and chemical modifications to the peptide backbone that reduce DPP-4 susceptibility.
What this means practically:
- After a single weekly dose, plasma concentrations remain clinically meaningful throughout the week, falling to their trough (lowest point) just before the next injection is due.
- After stopping semaglutide entirely, it takes approximately 5 weeks (5 half-lives) for the drug to be substantially cleared from the body. Plasma concentrations at that point are less than 5% of their steady-state level.
- Missing a single weekly dose results in plasma levels dropping toward sub-therapeutic range by the end of the second week, which is why the standard guidance is to inject as soon as possible if a dose is missed within a certain window, and to skip and resume regular dosing if outside that window. Your clinician determines which applies to you.
What is the half-life of tirzepatide?
Compounded tirzepatide has a half-life of approximately 5 days. Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 receptor. Like semaglutide, it uses fatty-acid conjugation to extend its duration of action, enabling once-weekly dosing.
After stopping tirzepatide:
- Substantial clearance occurs over approximately 4–5 weeks.
- Appetite and gastric-emptying effects progressively diminish over that window as plasma concentrations fall.
- The end-of-week trough is slightly more pronounced with tirzepatide than with semaglutide given the shorter half-life, which can make injection-day timing more noticeable for some patients.
Your own GLP-1 lasts about 90 seconds; the medications are engineered to last days — which is the whole reason once-weekly dosing works.
What happens to your body when GLP-1 medication clears?
GLP-1 receptor agonists do not permanently alter appetite physiology. When the medication clears, the receptor activation diminishes, and the body’s own appetite signaling — which the medication was suppressing — returns.
This is why weight regain after stopping GLP-1 medication is well-documented in clinical literature. The medication supports a caloric deficit; it does not reprogramme appetite setpoints in a lasting way. Patients who discontinue without having established durable dietary and lifestyle changes typically regain a significant proportion of lost weight within 12 months.
This is not a failure of the medication — it reflects the chronic nature of weight management physiology. GLP-1 receptor agonist therapy is increasingly viewed by clinicians as long-term or indefinite treatment, not a short-course intervention.
Why half-life matters for missed doses
The extended half-life of GLP-1 receptor agonists provides a practical buffer for missed doses. Unlike medications with a 4–6 hour half-life where a missed dose creates a significant pharmacological gap quickly, a missed weekly semaglutide or tirzepatide dose still leaves meaningful plasma concentrations for several days after the expected injection day.
Standard guidance for a missed GLP-1 dose generally follows this pattern (confirm the exact rule with your prescribing clinician):
- Missed by less than 2–3 days: Administer as soon as you remember, then resume your regular weekly schedule.
- Missed by 3+ days from scheduled day: Skip the missed dose and resume on your normal next scheduled day. Do not double-dose.
Frequently asked questions
How long does GLP-1 stay in your system?
It depends on the specific molecule. Native GLP-1 peptide has a half-life of approximately 1–2 minutes because it is rapidly degraded by the enzyme DPP-4. GLP-1 receptor agonist medications are engineered to resist that degradation. Compounded semaglutide has a half-life of approximately 7 days; compounded tirzepatide has a half-life of approximately 5 days. That is why both are dosed once weekly.
How long does semaglutide stay in your system?
Semaglutide has a half-life of approximately 7 days. After stopping semaglutide, it takes roughly 5 weeks (5 half-lives) for the drug to be substantially cleared from your system. Weight and appetite effects may persist or diminish over several weeks following discontinuation.
How long does tirzepatide stay in your system?
Tirzepatide has a half-life of approximately 5 days. After stopping tirzepatide, it takes approximately 4–5 weeks for the drug to be substantially cleared from your system.
What happens when GLP-1 wears off?
When GLP-1 receptor agonist levels fall below therapeutic thresholds — whether due to a missed dose or discontinuation — appetite signals typically return toward pre-treatment levels. Gastric emptying speeds back up, and satiety cues that the medication supported diminish. This is why most patients who stop GLP-1 medication without lifestyle changes in place experience weight regain.
Can you feel when GLP-1 medication wears off?
Some patients notice increased hunger or faster gastric emptying in the 12–24 hours before their weekly injection is due. This is sometimes called the "end-of-week" effect. It is not dangerous — it reflects the tail end of that dose's pharmacokinetic curve — and is one reason consistent weekly dosing on the same day each week is recommended.
Does GLP-1 medication leave your system faster if you exercise more?
Not meaningfully. GLP-1 receptor agonists like semaglutide and tirzepatide are metabolized via protein degradation pathways that are not significantly accelerated by exercise. Clearance is primarily determined by the half-life of the specific molecule.